In this study, ASTs are found to have significant therapeutic effects on cholestatic liver disease, which are the main active site of AR against CLD, astragaloside I and cycloastragenol significantly inhibit the progression of cholestatic liver disease, which may the most important active constituents of ASTs for CLD. The gene discussed is AR; the disease is congenital secretory chloride diarrhea 1.